Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
Institut Gustave Roussy · Vrije Universiteit Amsterdam · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,362
total citations
- FWCI
- 61.57
- Percentile
- 100%
- References
- 53
Citations per year
Authors
11Topics & keywords
Topics
Keywords
- Trametinib
- Dabrafenib
- Medicine
- Internal medicine
- Clinical endpoint
- Lung cancer
- Adverse effect
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.